The management of both male and female @entity1 with @entity29 ( @entity29 ) who wish to have a baby is challenging. For @entity1 , the most important factor to bear in mind is that the outcome of pregnancy is largely influenced by disease activity at the time of conception. @entity1 with quiescent disease are likely to have an uncomplicated pregnancy with the delivery of a healthy baby, whereas @entity1 with @entity66 are more likely to have complications such as @entity2208 , @entity2208 , stillbirths, and exacerbation of the disease. This is more true of @entity1 with @entity30 than of @entity1 with @entity31 . Although the safety of medications used during pregnancy is an important issue, the impact of the medications used to treat @entity29 is less important in comparison to disease activity itself. @entity2983 ( @entity3504 ) products appear to be safe during pregnancy; @entity288 are probably safe; @entity4446 and @entity500 should be used with caution; and @entity1499 is contraindicated. There are inadequate data on the use of infliximab during pregnancy. In regard to @entity1 with @entity29 , the disease itself does not seem to have any negative impact on fertility. However, there is controversy about the effects of using @entity4446 and @entity500 prior to and during fertilization. In view of possible adverse pregnancy outcomes, it would be prudent to withhold @entity4446 and @entity500 therapy in @entity1 with @entity29 for 3 months prior to conception, when feasible. Most @entity29 medications should be continued before, during, and after pregnancy, with careful attention to the known cautions and exceptions. If @entity29 in a pregnant @entity1 is in remission, the prognosis for pregnancy is the same as if she did not have @entity29 . @entity66 should therefore be treated aggressively and remission accomplished before pregnancy is attempted. Similarly, a @entity1 who unexpectedly becomes pregnant while her @entity29 is active should be treated aggressively, as remission remains the greatest investment for a favorable pregnancy outcome.

XXXX During Pregnancy.

@entity1 :: ('9606', 'Species') :: ['men', 'women', 'patients', 'woman', 'Women', 'patient'] @entity2208 :: ('MESH:D000022', 'Disease') :: ['spontaneous abortions', 'miscarriages'] @entity66 :: ('MESH:D004194', 'Disease') :: ['Active disease', 'active disease'] @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis'] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'IBD'] @entity4446 :: ('MESH:D015122', 'Chemical') :: ['6-mercaptopurine'] @entity3504 :: ('CHEBI:6775', 'Chemical') :: ['5-ASA'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"] @entity2983 :: ('MESH:D019804', 'Chemical') :: ['5-Aminosalicylic acid'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity29 :: (MESH:D015212,Disease) :: ['Inflammatory Bowel Disease']
